OBIO
Price
$4.65
Change
+$0.42 (+9.93%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
239.41M
Intraday BUY SELL Signals
RXRX
Price
$4.04
Change
-$0.13 (-3.12%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.1B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OBIO vs RXRX

Header iconOBIO vs RXRX Comparison
Open Charts OBIO vs RXRXBanner chart's image
Orchestra BioMed Holdings
Price$4.65
Change+$0.42 (+9.93%)
Volume$4.68K
Capitalization239.41M
Recursion Pharmaceuticals
Price$4.04
Change-$0.13 (-3.12%)
Volume$202.34K
Capitalization2.1B
OBIO vs RXRX Comparison Chart in %
OBIO
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
OBIO vs. RXRX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OBIO is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (OBIO: $4.24 vs. RXRX: $4.16)
Brand notoriety: OBIO and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OBIO: 142% vs. RXRX: 51%
Market capitalization -- OBIO: $263.13M vs. RXRX: $2.1B
OBIO [@Biotechnology] is valued at $263.13M. RXRX’s [@Biotechnology] market capitalization is $2.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OBIO’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • OBIO’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, OBIO is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OBIO’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • OBIO’s TA Score: 3 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, OBIO is a better buy in the short-term than RXRX.

Price Growth

OBIO (@Biotechnology) experienced а +3.41% price change this week, while RXRX (@Biotechnology) price change was -11.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

RXRX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.1B) has a higher market cap than OBIO($239M). OBIO YTD gains are higher at: 6.000 vs. RXRX (-38.462). OBIO has higher annual earnings (EBITDA): -70.94M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. OBIO (33.9M). OBIO has less debt than RXRX: OBIO (16.4M) vs RXRX (88.1M). RXRX has higher revenues than OBIO: RXRX (64.5M) vs OBIO (2.94M).
OBIORXRXOBIO / RXRX
Capitalization239M2.1B11%
EBITDA-70.94M-583.64M12%
Gain YTD6.000-38.462-16%
P/E RatioN/AN/A-
Revenue2.94M64.5M5%
Total Cash33.9M525M6%
Total Debt16.4M88.1M19%
TECHNICAL ANALYSIS
Technical Analysis
OBIORXRX
RSI
ODDS (%)
Bearish Trend 2 days ago
48%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
55%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
51%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 24 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
75%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
OBIO
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IBCGX13.620.03
+0.22%
VY® Baron Growth S2
SVLCX34.680.02
+0.06%
Columbia Select Large Cap Value C
AHSAX21.73N/A
N/A
Alger Health Sciences A
IPLSX29.37-0.19
-0.64%
Voya Index Plus LargeCap Port S
TROZX22.96-0.19
-0.82%
T. Rowe Price International Value Eq Z

OBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, OBIO has been loosely correlated with RXRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if OBIO jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OBIO
1D Price
Change %
OBIO100%
+2.66%
RXRX - OBIO
40%
Loosely correlated
+0.97%
XBIT - OBIO
38%
Loosely correlated
-4.86%
RGNX - OBIO
37%
Loosely correlated
+0.94%
BEAM - OBIO
37%
Loosely correlated
-0.36%
OCUL - OBIO
37%
Loosely correlated
-1.09%
More